A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Wassim Fares, MD, MSc, FCCP
Mannkind Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Valdi
Fresno, California, United States
- Palmtree Clinical Research
Palm Springs, California, United States
- Innova Pharma Research
Doral, Florida, United States
- New Life Medical Research
Hialeah, Florida, United States
- New Access Research and Medical Services
Miami, Florida, United States
- Southeastern Research Center
Winston-Salem, North Carolina, United States
- Low Country Research
Charleston, South Carolina, United States
- Metroplex Pulmomary & Sleep Center
McKinney, Texas, United States
- Pulmonary Medicine Consultants
McKinney, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2025
- Primary completion
- 17 Jun 2026
- Completion
- 17 Jun 2026
- Last update posted
- 22 Jul 2026
- Registered enrollment
- 27
- Registry id
- NCT07344558
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.